BR112019000788A2 - anticorpo, polinucleotídeo isolado, vetor de expressão, célula hospedeira ou sistema de expressão isento de células, métodos para produção de um anticorpo e para tratamento da psoríase, artrite psoriática ou dermatite atópica, e, composição farmacêutica - Google Patents

anticorpo, polinucleotídeo isolado, vetor de expressão, célula hospedeira ou sistema de expressão isento de células, métodos para produção de um anticorpo e para tratamento da psoríase, artrite psoriática ou dermatite atópica, e, composição farmacêutica

Info

Publication number
BR112019000788A2
BR112019000788A2 BR112019000788-1A BR112019000788A BR112019000788A2 BR 112019000788 A2 BR112019000788 A2 BR 112019000788A2 BR 112019000788 A BR112019000788 A BR 112019000788A BR 112019000788 A2 BR112019000788 A2 BR 112019000788A2
Authority
BR
Brazil
Prior art keywords
antibody
methods
atopic dermatitis
psoriatic arthritis
producing
Prior art date
Application number
BR112019000788-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Frederic Jerome Blanchetot Christophe
Ursø Birgitte
Skak-Nielsen Tine
Bertelsen Malene
Van Der Woning Sebastian
Saunders Michael
Joseph Wilhelmus De Haard Johannes
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of BR112019000788A2 publication Critical patent/BR112019000788A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112019000788-1A 2016-07-15 2017-07-14 anticorpo, polinucleotídeo isolado, vetor de expressão, célula hospedeira ou sistema de expressão isento de células, métodos para produção de um anticorpo e para tratamento da psoríase, artrite psoriática ou dermatite atópica, e, composição farmacêutica BR112019000788A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1612337.4 2016-07-15
GBGB1612337.4A GB201612337D0 (en) 2016-07-15 2016-07-15 Ant-il-22r antibodies
PCT/EP2017/067923 WO2018011420A1 (en) 2016-07-15 2017-07-14 Anti-il-22r antibodies

Publications (1)

Publication Number Publication Date
BR112019000788A2 true BR112019000788A2 (pt) 2019-07-02

Family

ID=56890507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000788-1A BR112019000788A2 (pt) 2016-07-15 2017-07-14 anticorpo, polinucleotídeo isolado, vetor de expressão, célula hospedeira ou sistema de expressão isento de células, métodos para produção de um anticorpo e para tratamento da psoríase, artrite psoriática ou dermatite atópica, e, composição farmacêutica

Country Status (28)

Country Link
US (4) US10696741B2 (https=)
EP (2) EP4023674A3 (https=)
JP (1) JP7163275B2 (https=)
KR (2) KR102571012B1 (https=)
CN (1) CN109641966B (https=)
AU (1) AU2017296094B2 (https=)
BR (1) BR112019000788A2 (https=)
CA (1) CA3024370A1 (https=)
CY (1) CY1125041T1 (https=)
DK (1) DK3484921T3 (https=)
ES (1) ES2903412T3 (https=)
GB (1) GB201612337D0 (https=)
HR (1) HRP20220197T1 (https=)
HU (1) HUE057615T2 (https=)
IL (1) IL264262B2 (https=)
LT (1) LT3484921T (https=)
MX (1) MX2019000539A (https=)
MY (1) MY197821A (https=)
PL (1) PL3484921T3 (https=)
PT (1) PT3484921T (https=)
RS (1) RS62884B1 (https=)
RU (1) RU2758721C2 (https=)
SA (1) SA519400856B1 (https=)
SG (1) SG11201900128XA (https=)
SI (1) SI3484921T1 (https=)
UA (1) UA125585C2 (https=)
WO (1) WO2018011420A1 (https=)
ZA (1) ZA201807816B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
KR20210019464A (ko) 2018-06-05 2021-02-22 바이오아트라, 인코퍼레이티드 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
CN110302363B (zh) * 2019-07-04 2020-10-09 北京大学第三医院（北京大学第三临床医学院） Il-22作为制备治疗pcos药物的应用及药物制剂
JP7789368B2 (ja) * 2020-05-29 2025-12-22 学校法人 久留米大学 炎症性腸疾患に対する治療用抗体
JP2025520166A (ja) 2022-06-03 2025-07-01 レオ ファーマ アクティーゼルスカブ Ｉｌ－２２ｒ抗体の液体製剤
EP4704974A1 (en) 2023-03-08 2026-03-11 LEO Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
JP2007525438A (ja) * 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
AU2005299809B2 (en) * 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
BRPI0619118A2 (pt) * 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
UA105405C2 (ru) * 2009-11-19 2014-05-12 Мерк Сероно С.А. Гуманизированное антитело против человеческого il-22ra
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2791170A1 (en) * 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2977386A1 (en) 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US10093737B2 (en) * 2013-03-01 2018-10-09 Albert Einstein College Of Medicine, Inc. HHLA2 as a novel inhibitor of human immune system and uses thereof
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies

Also Published As

Publication number Publication date
US11261246B2 (en) 2022-03-01
RU2758721C2 (ru) 2021-11-01
US10696741B2 (en) 2020-06-30
CN109641966A (zh) 2019-04-16
PT3484921T (pt) 2022-01-26
ES2903412T3 (es) 2022-04-01
AU2017296094A1 (en) 2018-12-13
JP2019528046A (ja) 2019-10-10
KR20230128137A (ko) 2023-09-01
MX2019000539A (es) 2019-10-04
CA3024370A1 (en) 2018-01-18
GB201612337D0 (en) 2016-08-31
SA519400856B1 (ar) 2022-10-25
IL264262A (en) 2019-02-28
HUE057615T2 (hu) 2022-05-28
KR102571012B1 (ko) 2023-08-24
IL264262B2 (en) 2024-11-01
EP3484921A1 (en) 2019-05-22
EP4023674A2 (en) 2022-07-06
PL3484921T3 (pl) 2022-03-28
UA125585C2 (uk) 2022-04-27
RU2019103991A3 (https=) 2021-04-29
AU2017296094B2 (en) 2024-02-01
LT3484921T (lt) 2022-01-10
US20230088269A1 (en) 2023-03-23
SI3484921T1 (sl) 2022-02-28
EP4023674A3 (en) 2022-10-05
IL264262B1 (en) 2024-07-01
JP7163275B2 (ja) 2022-10-31
WO2018011420A1 (en) 2018-01-18
DK3484921T3 (da) 2022-02-07
NZ748737A (en) 2025-06-27
MY197821A (en) 2023-07-18
ZA201807816B (en) 2026-03-25
KR20190026766A (ko) 2019-03-13
US20200157207A1 (en) 2020-05-21
SG11201900128XA (en) 2019-02-27
HRP20220197T1 (hr) 2022-04-29
CY1125041T1 (el) 2023-03-24
RS62884B1 (sr) 2022-03-31
US20200216528A1 (en) 2020-07-09
EP3484921B1 (en) 2021-11-17
RU2019103991A (ru) 2020-08-17
US11447544B2 (en) 2022-09-20
US20190127459A1 (en) 2019-05-02
CN109641966B (zh) 2022-08-23

Similar Documents

Publication Publication Date Title
BR112019000788A2 (pt) anticorpo, polinucleotídeo isolado, vetor de expressão, célula hospedeira ou sistema de expressão isento de células, métodos para produção de um anticorpo e para tratamento da psoríase, artrite psoriática ou dermatite atópica, e, composição farmacêutica
BR112018076281A2 (pt) imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
AR115389A1 (es) Anticuerpo antagonista de cd73
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
BR112019010943A8 (pt) Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
BR112018068340A2 (pt) imunoglobulinas de ligação ao tgfss1 e usos destas
BR112015030892A2 (pt) Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno
BR112016020009A2 (pt) anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
AU2015347015A8 (en) Antibody drug conjugates
BR112019005129A2 (pt) anticorpos anti-pd-1
BR112018075434A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
MX2024010985A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
TN2018000289A1 (en) Antibodies for il-17c
BR112021017860A2 (pt) Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]